文献速递消化内镜

瑞马唑仑与咪达唑仑在消化内镜中度镇静中的比较:随机对照试验的系统综述与Meta分析

Remimazolam versus midazolam for moderate sedation in gastrointestinal endoscopy: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Gastrointest Endosc · 2026-06-26

该系统综述与Meta分析纳入9项RCT共1251例患者,比较瑞马唑仑与咪达唑仑在消化内镜镇静中的效果。瑞马唑仑的镇静成功率与咪达唑仑无显著差异,但诱导时间、完全清醒时间、恢复时间和离院时间均显著缩短,患者满意度更高,低血压和心动过缓风险更低。

要点

  • 瑞马唑仑诱导、清醒、恢复和离院时间均显著短于咪达唑仑。
  • 瑞马唑仑患者满意度更高,低血压和心动过缓风险更低。

核心结论

  • 瑞马唑仑在消化内镜镇静中成功率与咪达唑仑相当,但恢复更快、满意度更高、低血压和心动过缓风险更低。
  • 瑞马唑仑可能成为消化内镜程序性镇静中更安全高效的替代选择。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Cochrane CENTRAL、Google Scholar和ClinicalTrials.gov从建库至2026年3月。
  • 纳入9项比较瑞马唑仑与咪达唑仑用于消化内镜镇静的随机对照试验,共1251例患者。
  • 使用RStudio进行统计分析。

关键数值与推荐

  • 其他不良事件两组相当。

临床怎么用

  • 消化内镜镇静可考虑选用瑞马唑仑以加快诱导和恢复、缩短离院时间。
  • 对低血压或心动过缓风险较高的患者,瑞马唑仑可能更安全。

局限性

  • 多个结局存在显著异质性,需谨慎解读结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Sedation is commonly used during GI endoscopy to improve patient comfort and procedural tolerance. Midazolam is a widely used agent but may be associated with adverse effects and delayed recovery. Remimazolam, an ultrashort-acting benzodiazepine, has emerged as a potential alternative with rapid onset and recovery. The aim of this review is to compare remimazolam with midazolam for sedation in patients undergoing GI endoscopy. METHODS: A systematic search was conducted across PubMed, Cochrane CENTRAL Library, Google Scholar, and ClinicalTrials.gov from inception till March 2026. Only randomized controlled trials (RCTs) comparing remimazolam with midazolam for sedation in GI endoscopy and reporting any outcome of interest were considered eligible. Statistical analysis was performed using RStudio (R Foundation for Statistical Computing, Vienna, Austria). RESULTS: A total of 9 RCTs involving 1251 patients were included. Meta-analysis showed no significant difference in sedation success (risk ratio, 1.49; P = .08) between remimazolam and midazolam in patients undergoing GI endoscopy. However, compared with midazolam, remimazolam significantly reduced induction time (mean difference [MD], -4.39 minutes; P = .04), time to full alertness (MD, -4.65 minutes; P = .012), recovery time (MD, -15.66 minutes; P ≤ .001), and discharge time (MD, -7.62 minutes; P = .04), and was associated with significantly higher patient satisfaction (standardized MD, 0.34; P < .01). In addition, remimazolam significantly reduced the risk of hypotension (odds ratio [OR], 0.47; P < .001) and bradycardia (OR, 0.59; P = .037), while other adverse events were comparable between groups. CONCLUSIONS: Remimazolam demonstrated sedation success comparable to midazolam in patients undergoing GI endoscopy. However, it was associated with faster induction and recovery times, higher patient satisfaction, and a lower risk of hypotension and bradycardia. These findings suggest that remimazolam may represent a safer and more efficient alternative to midazolam for procedural sedation during GI endoscopy. Nevertheless, substantial heterogeneity observed across several outcomes warrants cautious interpretation of these findings.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Akram U, Ahmad E, Ahmed S, et al. Remimazolam versus midazolam for moderate sedation in gastrointestinal endoscopy: a systematic review and meta-analysis of randomized controlled trials. Gastrointest Endosc. 2026. PMID: 42362034. doi:10.1016/j.gie.2026.06.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。